Drug intelligence / Profile preview

alstonia boonei crude saponin fraction

Development stage
Preclinical
Administration
Oral
01

Overview

**Alstonia boonei crude saponin fraction** is a phytochemical extract derived from the stem bark of Alstonia boonei, a plant widely used in African traditional medicine. The crude saponin fraction is prepared through solvent extraction, primarily using water and n-butanol, and subsequent precipitation. LC-MS analysis identifies this fraction as rich in saponins (notably lactone and triterpenoid saponins such as gardenoside, alpha-carboxy-delta-decalactone, 3-O-cis-coumaroylmaslinic acid, 3\u03b1-O-trans-feruloyl-2\u03b1-hydroxy-12-ursen-28-oic acid, and lucidumol A)[1]. Pharmacologically, the fraction demonstrates **inhibitory activity against pancreatic lipase, \u03b1-amylase, and \u03b1-glucosidase**, suggesting mechanisms relevant for obesity and diabetes, mostly by interfering with digestive enzymes central to carbohydrate and fat absorption and metabolism[1][3]. The extract also exhibits antiadipogenic effects in vitro (reducing lipid accumulation in adipocytes) and has reported antioxidant activity[2][5].

Other names
alstonia boonei saponin fractionA. boonei crude saponin fractionalstonia boonei stem bark saponin fraction
02

Targets

PNLIP (Pancreatic triacylglycerol lipase)AMY (Pancreatic alpha-amylase)Sucrase-Isomaltase

Beyond the preview

Go deeper on alstonia boonei crude saponin fraction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alstonia boonei crude saponin fraction.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call